| Janet S Abadir, MD | |
|
105 W 8th Ave, Ste 7010, Spokane, WA 99204-2302 | |
| (509) 747-6194 | |
| (509) 838-0824 |
| Full Name | Janet S Abadir |
|---|---|
| Gender | Female |
| Speciality | General Surgery |
| Experience | 24 Years |
| Location | 105 W 8th Ave, Spokane, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023117421 | NPI | - | NPPES |
| 2016893 | Medicaid | WA | |
| 292108 | Other | LABOR & INDUSTRIES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | MD-13266 (Hawaii) | Secondary |
| 208600000X | Surgery | MD60266345 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Kodiak Island Medical Ctr | Kodiak, AK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Providence Health And Services Washington | 5799675120 | 15 |
News Archive
Data presented today at the EULAR 2011 Annual Congress demonstrated that initial treatment with adalimumab (Humira, ADA) plus methotrexate in early RA patients can provide high levels of disease control in many patients, and may also offer the opportunity to change future treatment options for some.
Despite the great successes of targeted cancer drugs and the promise of novel immunotherapies, the vast majority of people diagnosed with cancer are still first treated with chemotherapy. Now a new study by UCSF researchers using techniques drawn from computational biology could make it much easier for physicians to use the genetic profile of a patient's tumor to pick the chemotherapy treatment with the fewest side effects and best chance of success.
Elderly patients taking the commonly prescribed blood thinner warfarin experience an increased risk for osteoporosis-linked bone fractures, according to a study at Washington University School of Medicine in St. Louis.
Researchers at Duke University Medical Center (DCRI) in the United States say there is disparity in the treatment men and women receive for heart failure in hospitals.
Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.
› Verified 9 days ago
| Entity Name | Providence Health & Services Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952430902 PECOS PAC ID: 5799675120 Enrollment ID: O20040318000605 |
News Archive
Data presented today at the EULAR 2011 Annual Congress demonstrated that initial treatment with adalimumab (Humira, ADA) plus methotrexate in early RA patients can provide high levels of disease control in many patients, and may also offer the opportunity to change future treatment options for some.
Despite the great successes of targeted cancer drugs and the promise of novel immunotherapies, the vast majority of people diagnosed with cancer are still first treated with chemotherapy. Now a new study by UCSF researchers using techniques drawn from computational biology could make it much easier for physicians to use the genetic profile of a patient's tumor to pick the chemotherapy treatment with the fewest side effects and best chance of success.
Elderly patients taking the commonly prescribed blood thinner warfarin experience an increased risk for osteoporosis-linked bone fractures, according to a study at Washington University School of Medicine in St. Louis.
Researchers at Duke University Medical Center (DCRI) in the United States say there is disparity in the treatment men and women receive for heart failure in hospitals.
Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Janet S Abadir, MD 105 W 8th Ave, Ste 7010, Spokane, WA 99204-2302 Ph: (509) 747-6194 | Janet S Abadir, MD 105 W 8th Ave, Ste 7010, Spokane, WA 99204-2302 Ph: (509) 747-6194 |
News Archive
Data presented today at the EULAR 2011 Annual Congress demonstrated that initial treatment with adalimumab (Humira, ADA) plus methotrexate in early RA patients can provide high levels of disease control in many patients, and may also offer the opportunity to change future treatment options for some.
Despite the great successes of targeted cancer drugs and the promise of novel immunotherapies, the vast majority of people diagnosed with cancer are still first treated with chemotherapy. Now a new study by UCSF researchers using techniques drawn from computational biology could make it much easier for physicians to use the genetic profile of a patient's tumor to pick the chemotherapy treatment with the fewest side effects and best chance of success.
Elderly patients taking the commonly prescribed blood thinner warfarin experience an increased risk for osteoporosis-linked bone fractures, according to a study at Washington University School of Medicine in St. Louis.
Researchers at Duke University Medical Center (DCRI) in the United States say there is disparity in the treatment men and women receive for heart failure in hospitals.
Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.
› Verified 9 days ago
Paul C Thorne, MD Surgery Medicare: Medicare Enrolled Practice Location: 101 W 8th Ave, Ste 100, Spokane, WA 99204 Phone: 509-474-5445 Fax: 509-462-4086 | |
Mary Cristina Smith, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 62 W 7th Ave Ste 110, Spokane, WA 99204 Phone: 509-456-0262 Fax: 509-462-5059 | |
Dr. Dara Heisler Christante, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 217 W Cataldo Ave Fl 3, Spokane, WA 99201 Phone: 509-624-2326 Fax: 509-252-2509 | |
Dr. Luke Xiaoli Zhan, M.D., PH.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 122 W 7th Ave, Suite 420, Spokane, WA 99204 Phone: 509-626-9440 Fax: 509-626-9475 | |
Paul E Myers, MD Surgery Medicare: Medicare Enrolled Practice Location: 910 W 5th Ave, Suite 800, Spokane, WA 99204 Phone: 509-838-2531 | |
Dr. Jenna Kochevar, DO Surgery Medicare: Accepting Medicare Assignments Practice Location: 910 W 5th Ave Ste 800, Spokane, WA 99204 Phone: 509-755-5120 Fax: 509-755-6580 |